I have long been an investor in RVX and Zenith, and I believe in the benefits of the science to patients who need these medications. I, in particular, like the inflammation reducing benefits from Apabetalone and see it being useful as among other things a drug which can reduce the need for Prednisone which my family has benefitted from and also suffered from. I also believe the benefits will have a role to plan in many other diseases which are not yet being considered.

It is my desire to get dividends from both RVX and from Zenith Capital. I do not want capital gains which, mean I must then look for further investments in which to place the after tax proceeds. I believe that an option will be to sell Apabetalone and other related drugs from RVX and have royalties and proceeds come into RVX which than can use the proceeds to pay dividends

I believe that it will be best for us as shareholders to continue on for the ride in the development of the other medications and I hope that management (if they sell off Zenith epigenitics Ltd) retains the proceeds in Zenith Capital and sets up another subsidiary to carry out further research on other drugs in its pipeline

It can do this and collect royalties from the company which commercializes Apabetalone, and can also pay dividends to shareholders from the further commercialization of ZEN3694